Wells Fargo analyst Larry Biegelsen maintained a Buy rating on GE Healthcare Technologies Inc (GEHC – Research Report) yesterday and set a price target of $89.00.
Larry Biegelsen has given his Buy rating due to a combination of factors that highlight GE Healthcare Technologies Inc’s potential for growth despite some challenges. The company reported a solid performance in the first quarter, with organic growth of approximately 4% and earnings per share surpassing expectations. Although GEHC has adjusted its 2025 guidance due to an $0.80 incremental tariff impact, the company anticipates mitigating these effects by 2026.
Moreover, GEHC’s management remains optimistic about the future, expecting a recovery in China sales in the latter half of 2025 and a positive outlook for hospital capital expenditures in Europe and the U.S. Additionally, the launch of new products like Flyrcado is expected to contribute to sales growth. The company’s substantial backlog and strong order growth further support the Buy rating, indicating a healthy underlying market demand.
According to TipRanks, Biegelsen is a 5-star analyst with an average return of 8.2% and a 53.88% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Dexcom, Abbott Laboratories, and Boston Scientific.
In another report released yesterday, BTIG also reiterated a Buy rating on the stock with a $82.00 price target.